Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Vertex Pharmaceuticals, Inc shares valued at $280,522 were purchased by Biller Jonathan on Oct 02 ’25. At $404.21 per share, Biller Jonathan acquired 694 shares.
Also, Bhatia Sangeeta N. sold 266 shares, netting a total of over 102,860 in proceeds. Following the sale of shares at $386.69 each, the insider now holds 4,565 shares.
Before that, Bhatia Sangeeta N. had added 266 shares to its account. In a trade valued at $102,860, the Director bought Vertex Pharmaceuticals, Inc shares for $386.69 each.
As published in a research note from Leerink Partners on September 25, 2025, Vertex Pharmaceuticals, Inc [VRTX] has been rated up from a Market perform to an Outperform and the price target has been revised to $456. Analysts at Raymond James started covering the stock with ‘”a Mkt perform”‘ outlook in a report released in early September. As of August 06, 2025, Wells Fargo has increased its “an Equal weight” rating to a “an Overweight” for VRTX. Earlier on May 07, 2025, Wolfe Research downgraded its rating. Their new recommendation was “a Peer perform” for VRTX stock which previously was a “an Outperform”.
Analyzing VRTX Stock Performance
On last trading session, Vertex Pharmaceuticals, Inc [NASDAQ: VRTX] rose 1.15% to $408.85. The stock’s lowest price that day was $403.59, but it reached a high of $410.995 in the same session. During the last five days, there has been a surge of approximately 7.07%. Over the course of the year, Vertex Pharmaceuticals, Inc shares have dropped approximately -12.09%. Shares of the company reached a 52-week high of $519.68 on 03/14/25 and a 52-week low of $362.50 on 08/11/25.
Support And Resistance Levels for Vertex Pharmaceuticals, Inc (VRTX)
According to the 24-hour chart, there is a support level at 404.11, which, if violated, would cause prices to drop to 399.37. In the upper region, resistance lies at 412.29. The next price resistance is at 415.73. RSI (Relative Strength Index) is 61.13 on the 14-day chart, showing neutral technical sentiment.
Is Vertex Pharmaceuticals, Inc subject to short interest?
Stocks of Vertex Pharmaceuticals, Inc saw a sharp rise in short interest on 2025-09-15 jumping by 0.35 million shares to 4.05 million. Data from Yahoo Finance shows that the short interest on 2025-08-15 was 3.7 million shares. A jump of 8.71% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 2.83 of the overall float, the days-to-cover ratio (short ratio) jumped to 2.83.
Which companies own the most shares of Vertex Pharmaceuticals, Inc (VRTX)?
In terms of Vertex Pharmaceuticals, Inc share price expectations, FactSet research, analysts set an average price target of 467 in the next 12 months, up nearly 15.53% from the previous closing price of $404.21. Analysts anticipate Vertex Pharmaceuticals, Inc stock to reach 553 by 2025, with the lowest price target being 420. In spite of this, 16 analysts ranked Vertex Pharmaceuticals, Inc stock as Buy at the end of 2025. On May 06, 2025, Leerink Partners assigned a price target of “a Market perform” to the stock and downgraded coverage with a $503.
